Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they
are generally considered to have direct oncolysis and cancer immune effects. With the …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

Throughout its 40-year history, the field of gene therapy has been marked by many
transitions. It has seen great strides in combating human disease, has given hope to patients …

In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …

Oncolytic viruses have been taking the front stage in biological therapy for cancer recently.
The first and most potent virus to be used in oncolytic virotherapy is human adenovirus …

Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the
management of various cancers. Different concepts of modification within the adenovirus …

Pancreatic ductal adenocarcinoma (PDA) is characterized by its highly immunosuppressive
tumor microenvironment (TME) that limits T cell infiltration and induces T cell hypofunction …

The tumor microenvironment plays a pivotal role in tumor initiation and progression by
creating a dynamic interaction with cancer cells. The tumor microenvironment consists of …

Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and
finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into …